Literature DB >> 27015764

The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder.

Yuping Cao1, Jingjin Shen1,2, Wen Li3, Yu Zhang1, Xiaoyun Guo4, Chiang-Shan Li4, Yalin Zhang5, Xingguang Luo4,6.   

Abstract

There is little understanding of how unipolar major depressive disorder (UMDD) symptoms evolve in response to antidepressant treatment. The present research examined the associations between symptom trajectories and clinical remission in Chinese patients with UMDD. A total of 165 outpatients with UMDD received treatment of fluoxetine (20 mg/day) for 6 weeks and were assessed for symptom severity at weeks 1, 2, 4, and 6. We found that patients with UMDD show heterogeneity in treatment response to fluoxetine. Psychomotor retardation is a prominent symptom during the 6 weeks of assessment, and its severity at baseline is negatively associated with clinical remission.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  clinical remission; symptom; trajectory; unipolar major depressive disorder

Mesh:

Substances:

Year:  2016        PMID: 27015764      PMCID: PMC5035708          DOI: 10.1111/appy.12240

Source DB:  PubMed          Journal:  Asia Pac Psychiatry        ISSN: 1758-5864            Impact factor:   2.538


  5 in total

1.  Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.

Authors:  P Bech
Journal:  Int J Neuropsychopharmacol       Date:  2001-12       Impact factor: 5.176

Review 2.  Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.

Authors:  F Artigas; L Romero; C de Montigny; P Blier
Journal:  Trends Neurosci       Date:  1996-09       Impact factor: 13.837

3.  Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.

Authors:  Armin Szegedi; Matthias J Müller; Ion Anghelescu; Christoph Klawe; Ralf Kohnen; Otto Benkert
Journal:  J Clin Psychiatry       Date:  2003-04       Impact factor: 4.384

4.  Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).

Authors:  Craig H Mallinckrodt; Apurva Prakash; John P Houston; Ralph Swindle; Michael J Detke; Maurizio Fava
Journal:  Neuropsychobiology       Date:  2007-11-23       Impact factor: 2.328

5.  Residual symptoms after partial remission: an important outcome in depression.

Authors:  E S Paykel; R Ramana; Z Cooper; H Hayhurst; J Kerr; A Barocka
Journal:  Psychol Med       Date:  1995-11       Impact factor: 7.723

  5 in total
  1 in total

1.  Development and testing of the hemodialysis symptom distress scale (HSD-22) to identify the symptom cluster by using exploratory factor analysis.

Authors:  Mei-Chu Chen; Ya-Fang Ho; Chiu-Chu Lin; Chia-Chen Wu
Journal:  BMC Nephrol       Date:  2021-04-12       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.